Role of IFN kappa in psoriasis-mediated diabetes development
Role of IFN kappa in psoriasis-mediated diabetes development
批准号:
10513927
负责人:
Sonya J Wolf-Fortune
金额:
$9.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-10 至 2024-07-31
关键词:
AdipocytesAdipose tissueAnti-Inflammatory AgentsAutomobile DrivingAwardCardiovascular systemCellsChronicDataDevelopmentDiabetes MellitusDiseaseEnzymesEpigenetic ProcessFacultyFunctional disorderGLUT 4 proteinGene ExpressionGeneticGenetic ModelsHealthcare SystemsHomeostasisHumanHyperglycemiaImiquimodImpairmentInflammationInflammatoryInterferon Type IInterferonsJAK1 geneLaboratoriesLeadLesionLinkLiteratureMLL geneMediatingMetabolicMetabolic dysfunctionMethodsMolecularMorbidity - disease rateMusMyeloid CellsNon-Insulin-Dependent Diabetes MellitusPPAR gammaPatientsPharmacologyPhasePhenotypeProcessProductionPsoriasisPublishingRegulationResearchResearch PersonnelResearch TrainingRiskRisk FactorsRoleRunningSTAT1 geneSTAT3 geneSequence AnalysisSignal TransductionSkinSkin TissueTNF geneTechniquesTestingTimeTissue SampleTissuesTrainingbasechronic inflammatory skincostcytokineexperimental studyglucose metabolismglycemic controlhistone demethylasehistone methyltransferaseimprovedkeratinocytemacrophagemortalitynew therapeutic targetnoveloverexpressionperipheral bloodprogramsskillsskin disorderskin lesionsystemic inflammatory responsetargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Recent literature has identified that psoriasis, a prevalent chronic inflammatory skin disease, is associated with
an increased risk of type 2 diabetes (T2D). This is important since the combination of psoriasis and T2D worsen
glycemic control to a greater degree, leading to increased secondary complications than either disease alone;
however, the molecular mechanisms that predispose patients with psoriasis to develop T2D are unknown. In
psoriasis, interferon kappa (IFNκ), a type I IFN, is increased in skin lesions and peripheral blood, leading to
systemic inflammation. Our preliminary data identifies that a histone methyltransferase, Mixed lineage leukemia
protein 1 (MLL1), may control IFNκ expression in keratinocytes, and this may be mechanistically driven by
Tyk2/STAT1 signaling. This overexpression of IFNk by keratinocytes is associated with increased inflammatory
macrophages (MΦs) in skin and adipose tissue and hyperglycemia development. To this end, our preliminary
data identify that keratinocyte-derived IFNκ can drive MΦs towards an inflammatory phenotype via a JMJD3-
mediated mechanism. Further, our group has identified that JMJD3, a histone demethylase, is crucial in
regulating inflammatory MΦs in skin and is upregulated in MΦs following IFNκ/JAK1/STAT3 stimulation. This
K99/R00 proposal seeks to test the hypothesis that Tyk2/STAT1 signaling upregulates MLL1 in keratinocytes
and mechanistically underlies IFNκ overexpression in psoriasis. Further, we propose that this increase in IFNκ
by psoriatic keratinocytes drives MΦs towards an inflammatory phenotype in skin and adipose tissue via a
JMJD3-mediated mechanism. These inflammatory adipose tissue macrophages (ATMs) then drive adipocyte
metabolic dysfunction via regulation of PPARγ and GLUT4. To test these hypotheses, We will pursue the
following aims during the K99 phase of this award: AIM 1: Identify the MLL1-mediated mechanism(s) by which
keratinocyte IFNκ expression is regulated in psoriasis tissue, AIM 2: Examine the mechanism(s) by which
keratinocyte-derived IFNκ regulates MΦ phenotype in psoriasis. During this time, the PI will receive research
training in epigenetic techniques, isolating and culturing human keratinocytes, sequence analysis, and isolating
macrophages from adipose tissue. During the independent phase(R00), she will determine the mechanism(s)
by which ATM-derived TNFα dysregulates adipocyte glucose metabolism in psoriasis and determine if IFNκ
inhibition improves glucose metabolism (AIM 3). Training in the proposed techniques during the K99 phase will
afford the PI the necessary skills to run a successful independent research program studying the relationship
between chronic skin inflammation diseases and metabolic dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of IFN kappa in psoriasis-mediated diabetes development
-
批准号:10680608
-
项目类别:
-
资助金额:$9.0万
-
财政年份:2022
-
负责人:Sonya J Wolf-Fortune
-
依托单位:
海外基金